20 October 2015 - NICE has today published draft guidance recommending ezetimibe (Ezetrol, Merck Sharp & Dohme) as an option for some adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. The draft guidance updates NICE’s previous guidance.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-issues-draft-guidance-on-ezetimibe-for-primary-hypercholesterolaemia